Arieli Group and Bar-Ilan University's Tech Transfer Office, BIRAD, Announce Partnership to Accelerate the Commercialization of Pharmaceutical Research

The partnership aims to advance pharmaceutical and life sciences ventures originating from BIRAD- Bar-Ilan University, turning laboratory discoveries into solutions that address unmet medical needs.

RAMAT GAN, Israel and NEW YORK, March 19, 2025 /PRNewswire/ -- Arieli Group, a global investment firm, and BIRAD Research & Development Company Ltd., the technology transfer arm of Bar-Ilan University (BIU), have announced a partnership aimed at accelerating the commercialization of groundbreaking pharmaceutical and life sciences innovations developed by researchers at the University.

The partnership primarily targets the pharmaceutical and life sciences sectors, with a focus on advancing commercialization and technology transfer, bolstering BIRAD's efforts to translate academic research into solutions that address unmet medical needs.

Bar-Ilan University's renowned interdisciplinary research and world-class laboratories are developing cutting-edge technologies to benefit people globally. BIRAD continuously strives to transform this academic research into commercially viable solutions based on their strong expertise in licensing. Drawing on Arieli Group's diverse ecosystem and investment expertise, along with both partners' proven experience in venture creation and new technology development, the partnership is well positioned to support the advancement of pharmaceutical and life sciences technologies emerging from Bar-Ilan University.

This partnership marks a significant step in developing innovative technologies, with BIRAD and Arieli Group working together to foster scientific progress that will positively impact both industry and society. As a first step, nine world-renowned researchers from Bar-Ilan University in the fields of immuno-oncology, neuropsychiatry and neurodegenerative diseases have begun working with experts from Arieli Group and the healthcare and pharmaceutical industries to advance the development of transformative innovations being developed in their laboratories.

Established in 1955, Bar-Ilan University is one of Israel's largest academic institutions, with more than 20,000 students and over 800 senior faculty members. The University has a long history of commercializing cutting-edge technologies, driving groundbreaking advancements across multiple industries including healthcare, energy and more.

Professor Zeev Zalevsky, Vice President for Academia-Industry Relations, said: "The partnership with Arieli Group aims to bring the pharma ecosystem to BIU, bridging the financial gap between transformative research and commercialization. Furthermore, we aim to provide the researchers with strong entrepreneurial skills and the technical tools to further advance their technologies."

Evan Renov, Co-Founder and Managing Partner at Arieli Group, added: "At Arieli Group, we are committed to bringing our expertise and broad ecosystem to transform BIU's cutting-edge research into real-world solutions. Partnering with BIRAD to support the commercialization of Bar-Ilan University's life sciences and pharmaceutical technologies is a natural extension of our mission. Together, we are focused on turning groundbreaking academic research into impactful solutions that address critical unmet medical needs and contribute to the advancement of global health."

About Arieli Group:

Arieli Group is a global investment firm committed to creating enduring prosperity. We partner with visionary entrepreneurs to transform bold ideas into groundbreaking technologies that shape the future. With a forward-thinking approach, Arieli invests in early and growth-stage companies across industries including cybersecurity, defense, deep tech, healthcare, energy, fintech, and agritech. Rooted in a third-generation family office, Arieli is dedicated to building the next generation of technologies and driving them forward. For more information, visit www.arieli-group.com.

About BIRAD:

BIRAD – Research & Development Company Ltd. translates new inventions made at Bar-Ilan University into useful technologies and products that can be effectively commercialized, thus strengthening the economy, promoting innovation and improving lives.

BIRAD's innovative approach, combined with Bar-Ilan University's rapid growth leading Israel's growth in students' number, including the largest Nanotechnology center in Israel and new Medical School in Safed, provides BIRAD with a wide range of opportunities. Thus, BIRAD offer corporate partnerships and alliances, intellectual property management, and technology commercialization through venture creation, sponsored research and licensing. For more information, visit www.birad.biz.

Forward-Looking Statements

This release contains forward-looking information about Arieli Capital LLC ("Arieli") which involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Accordingly, any statements included in this communication are not statements of historical facts but may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements are, in some cases, accompanied by words such as "may," "should," "would," "could," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "seem," "seek," "continue," "future," "will," "expect," "outlook" or other similar words, phrases or expressions and the negatives of such words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding Arieli's expectations of future events, future opportunities, global expansion and other growth initiatives, and Arieli's investments in such initiatives. These statements are based on various assumptions and known or unknown risks, uncertainties and other factors, and actual results may differ materially. Neither Arieli nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Arieli assumes no obligation to update any forward-looking statements or information contained in this communication except to the extent required by law.

Contact:

BIRAD
Assaf E. Sagiv (PhD, MBA), VP Business Development
+972-50-622-0274; [email protected]

Arieli Group

Nataf Dgani, Head of Marketing
 +972-54-757-3384; nataf@arieli-group.com 

Nurit Kantarovitz, VP Strategic Partnerships
+972-54-441-6834; [email protected]

Photo - https://mma.prnewswire.com/media/2645309/Arieli_BIRAD_Team_Bio_Pitch_Event.jpg

SOURCE Arieli Group; BIRAD